Abstract
Hypertension increases the risk for many conditions, including ischaemic heart disease, heart failure, stroke, and kidney disease. 1 Thomopoulos C Parati G Zanchetti A Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014; 32: 2285-2295 Crossref PubMed Scopus (207) Google Scholar Hypertension frequently coexists with diabetes as obesity increases the risk of developing both conditions. In patients with diabetes, two-thirds also have hypertension. 2 Centers for Disease Control and PreventionNational Diabetes Statistics Report, 2020. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA2020 Google Scholar , 3 Chow CK Teo KK Rangarajan S et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013; 310: 959-968 Crossref PubMed Scopus (1143) Google Scholar In the USA, four of the top ten causes of death are associated with hypertension (ie, heart disease, stroke, diabetes, and renal disease). 4 Ahmad FB Anderson RN The leading causes of death in the US for 2020. JAMA. 2021; 325: 1829-1830 Crossref PubMed Scopus (247) Google Scholar Thus, strategies that reduce comorbidities associated with hypertension are important. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysisBlood pressure lowering is an effective strategy for the prevention of new-onset type 2 diabetes. Established pharmacological interventions, however, have qualitatively and quantitively different effects on diabetes, likely due to their differing off-target effects, with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favourable outcomes. This evidence supports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, which could further refine the selection of drug choice according to an individual's clinical risk of diabetes. Full-Text PDF Open Access
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
